MPN treatment: traditional, new and upcoming drug insights
Myeloproliferative neoplasms (MPNs) have traditionally been treated with hydroxyurea, which remains the gold standard of treatment. Excitingly, there are now novel treatments available in the clinic and more in the pipeline. In this insightful interview, Tiziano Barbui, MD, from Hospital Papa Giovanni XXIII, Bergamo, Italy, discusses the different therapies and the evidence backing their usage in different groups, including interferon and JAK2 inhibitors. This video was recorded at the Myeloproliferative Neoplasms Advances Day 2017 in London, UK.
Related videos
5:44
What is the best therapy for a young patient with relapsed/refractory CLL?
Jacqueline Barrientos
3:30
Thrombosis risk factors in MPNs
Tiziano Barbui
1:07
Genetic mutations may alter treatment courses for patients with MPNs
Alessandro Vannucchi
2:15
Increasing awareness and funding for metastatic breast cancer
Beth Roberts
1:49
Encouraging patients to ask about clinical trials
Simon Rule
